![Benjamin Hohl](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Vermogen: 2 M $ op 31-05-2026
Benjamin Hohl is currently CFO & Head-Corporate Development at Enliven Therapeutics, Inc., a position held since 2023.
Mr. Hohl completed undergraduate education at the University of California, Los Angeles.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 17-06-2026 | 51.000 ( 0,08% ) | 2 M $ | 31-05-2026 |
| Bedrijven | Functie | Begin |
|---|---|---|
| ENLIVEN THERAPEUTICS, INC. | Financieel Directeur/CFO | 23-02-2023 |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
| Bedrijven in privébezit | 2 |
|---|---|
University of California, Los Angeles
 University of California, Los Angeles Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Enliven Therapeutics, Inc.
 Enliven Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical stage precision oncology company that develops molecule therapies | Health Technology |
Kies jouw editie
Alle financiële informatie op nationaal niveau
